Drug intelligence / Profile preview

TQB3915

Development stage: Phase 1
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

TQB3915 is a selective estrogen receptor covalent antagonist (SERCA) developed as an oral small molecule therapy. It works by selectively and covalently binding to the estrogen receptor alpha (ERα), altering its conformation, and inhibiting its activity. This mechanism blocks intracellular signal transmission mediated by ERα, thereby inhibiting the growth and survival of ERα-expressing tumor cells. The drug is being investigated primarily for advanced malignant solid tumors, including breast cancer[1][2][3][4].

Other names: selective estrogen receptor covalent antagonist TQB3915

Targets

ESR1 (ERα)

Beyond the preview

Go deeper on TQB3915.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQB3915.

Explore the full profile